Supernus Pharma (SUPN) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Stifel Upgrades Supernus Pharmaceuticals (SUPN) to Buy, Would be Buyer On Weakness
November 8, 2017 4:30 AM ESTStifel upgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Hold to Buy with a price target of $47.00.
Analyst Annabel Samimy believes with the cash and balance sheet flexibility available to management, the company is well funded to pursue its growth programs which amplifies its... More
